Cancer Drug Shows Promise in Parkinson's Dementia Cancer Drug Shows Promise in Parkinson's Dementia
Low-dose nilotinib improved biomarkers, cognition, and motor skills in a small phase 1 study of patients with Parkinson's dementia and Lewy body dementia. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Dementia | Neurology | Neurosurgery | Nilotinib | Parkinson's Disease | Study | Tasigna